Protective effect of ursodeoxycholic acid upon the post-myocardial infarction heart [0.03%]
熊去氧胆酸对心肌梗塞后心脏的保护作用研究
Benedict Reilly-O&#x;Donnell,Elisa Ferraro,Ryan Brody et al.
Benedict Reilly-O&#x;Donnell et al.
A new PCSK-9 monoclonal antibody for lowering LDL-cholesterol and lipoprotein(a) in Chinese patients with familial hypercholesterolaemia [0.03%]
用于中国杂合子家族性高胆固醇血症患者降低低密度脂蛋白胆固醇和脂蛋白(a)的新型PCSK9单克隆抗体治疗研究
Seyed Saeed Tamehri Zadeh,Dick C Chan,Gerald F Watts
Seyed Saeed Tamehri Zadeh
Toll-like receptor 4 induces trained innate immune tolerance in the heart in a model of stress-induced cardiomyopathy [0.03%]
Toll样受体4在应激型心肌病模型中诱导心脏获得性固有免疫耐受性
Kenji Rowel Q Lim,Junedh Amrute,Attila Kovacs et al.
Kenji Rowel Q Lim et al.
Aims: Although the ability of the heart to adapt to environmental stress has been studied extensively, the molecular and cellular mechanisms responsible for cardioprotection are not yet fully understood. In this study, we...
Microplastics and nanoplastics: tiny threats for cardiovascular diseases? [0.03%]
微塑料和纳米塑料：对心血管疾病的潜在威胁？
Raffaele Marfella,Francesco Prattichizzo,Giuseppe Paolisso
Raffaele Marfella
Recaticimab in adult heterozygous familial hypercholesterolemia (REMAIN-3): A multicentre, randomised, double-blind, placebo-controlled phase 3 study [0.03%]
针对成人杂合子家族性高胆固醇血症患者的Recaticimab III期临床研究（REMAIN-3）：一项多中心、随机、双盲、安慰剂对照试验
Liwen Li,Yujie Zhou,Chanjuan Deng et al.
Liwen Li et al.
Aims: Heterozygous familial hypercholesterolemia (HeFH) is a genetic disorder, characterised by high plasma concentrations of low-density lipoprotein cholesterol (LDL-C) from birth. This study aimed to assess the efficacy...
In PLN-R14del mice, SR structure restoration, rather than calcium cycling, is the dominant effector of PLN-ASO treatment [0.03%]
在PLN-R14del小鼠中，PLN-ASO治疗的主要效应是SR结构的恢复，而不是钙循环
Liu Sun,Tim R Eijgenraam,Carl Amilon et al.
Liu Sun et al.
Aims: Phospholamban (PLN) acts as an inhibitory regulator of calcium uptake in the sarco-/endoplasmic reticulum (SR) of cardiomyocytes. The pathogenic variant, PLN-R14del, leads to dilated and/or arrhythmogenic cardiomyop...
In vitro and in vivo disease models of cardiac amyloidosis: progress, pitfalls and potential [0.03%]
心脏淀粉样变性的体内外疾病模型：进展、陷阱和潜力
Jiabin Qin,Zeping Qiu,Yingze Fan et al.
Jiabin Qin et al.
Amyloid light chain (AL) and transthyretin amyloidosis (ATTR)-induced cardiomyopathy are life-threatening protein misfolding disorders characterized by amyloid fibril deposition in the heart, which significantly impairs cardiac function. Th...
Vascular regenerative deficiencies in people with elevated lipoprotein(a): the Lp(a)-VRCE CardioLink-16 translational study [0.03%]
脂蛋白(a)升高人群的血管再生功能缺陷：Lp(a)-VRCE CardioLink-16转化研究
Michael Moroney,Jack H Casey,Hwee Teoh et al.
Michael Moroney et al.
Aims: Lipoprotein(a) [Lp(a)] is a causal risk factor for atherosclerotic cardiovascular disease (ASCVD); however, the relationship between Lp(a) and the capacity for vascular repair remains unclear. Depletion of vascular ...
ESC Congress: celebrating cardiovascular innovation, global collaborations, and patient-centered care [0.03%]
ESC大会：庆祝心血管创新、全球合作和以患者为中心的护理
Tomasz J Guzik,Thomas F Lüscher
Tomasz J Guzik